Tom Price, Trump’s pick to lead Health and Human Services, has an ethically questionable investment and legislative history. Just days after purchasing stock in Zimmer Biomet, for example, he turned around and introduced legislation that would significantly benefit this manufacturer of artificial joint replacements by delaying implementation of a Medicare rule to enhance safety and save taxpayer money. Now Trump wants him to lead the department that regulates companies like Zimmer Biomet as well as overseeing Medicare. Our elders deserve better than this.
A Dallas judge’s ruling resulted in a pyrrhic victory for Johnson & Johnson. The latest and possibly last chapter in a long-lasting court case came to a close at the beginning of January. For two years, Johnson & Johnson had been fighting six plaintiffs’ accusations of negligence. At the forefront of the drama was a
Stryker issued hazard alert for LFIT Anatomic CoCr V40 hips in conjunction with the Therapeutic Goods Administration (TGA), Australia’s equivalent of the U.S. FDA. At the time of this writing, no such action has been taken by the FDA.
A Los Angeles jury took just 3.5 hours to deliver a $9.2M Zimmer Durom Cup hip implant award. The award is the first plaintiff’s victory in the hundreds of pending suits against the company for failure to warn and negligent design of a defective product. The trial lasted three weeks. Plaintiff, Gary K., developed complications
This month, CBS affiliate WNEM reported that a settlement has been reached in a lawsuit over defective Stryker hips. In this defective hip replacement settlement, Stryker agreed to pay over $1.4 billion in damages to patients who received faulty implants. For more on defective hip replacements, check out our sister blog, DangerousDrugs WNEM writes, “Thousands
A long-awaited settlement was reached between Howmedica Osteonics Corp., manufacturer of the Stryker Rejuvenate and ABG II hip implants, and representatives for persons injured by these medical devices. The settlement includes encompasses claims brought in both the federal MDL pending in the District of Minnesota ( In re: Stryker Rejuvenate and ABG II Hip Implant
The New York Times reports on the interesting information being revealed in the first DePuy ASR hip trial: Separately, a DePuy engineer, Graham Isaac, testified on Thursday that before selling the A.S.R., the company only tested its performance on laboratory equipment at one angle of implantation. Depending on the surgical technique and a patient’s build,
Once again, the FDA arrives late to the party: Jan 17 (Reuters) – The U.S. Food and Drug Administration has issued a proposal calling on companies that make all-metal hip replacements to provide additional information proving they are safe and effective before being allowed to continue selling them. The move follows years of concern within
I spent several hours last week reviewing the evidence surrounding the DePuy ASR and ASR XL hip recall, and I’ve come to the conclusion that these are going to be great lawsuits from a damages perspective. Some people who received recalled DePuy hip replacements have had to undergo multiple hip replacement surgeries. The medical bills